Invitrocue, together with Angsana Molecular & Diagnostics Laboratory, has entered a strategic partnership with Averywell to introduce a next-generation, miRNA-based liquid biopsy solution for early lung cancer detection.

The collaboration integrates molecular diagnostics with existing LDCT workflows to improve risk stratification of lung nodules and support more informed clinical decision-making across Singapore and the broader Asia region.